The pathophysiology and pharmacological treatment of Huntington disease

Behavioural Neurology

Volumn 26, Issue 4, 2013, Pages 245-253

  Pidgeon, Connie ^a   Rickards, Hugh ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Chorea; dopamine; Huntington disease; non motor symptoms; pharmacotherapy; tetrabenazine

Indexed keywords

AMANTADINE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; BACLOFEN; CLOZAPINE; DIMEBON; DONEPEZIL; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUOXETINE; MODAFINIL; NABILONE; NEUROLEPTIC AGENT; PLACEBO; REMACEMIDE; RILUZOLE; SEROTONIN UPTAKE INHIBITOR; TETRABENAZINE; TIAPRIDE; UBIDECARENONE;

ARTICLE; BEHAVIOR DISORDER; CLINICAL FEATURE; COGNITIVE DEFECT; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FUNCTIONAL STATUS; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; NEUROPATHOLOGY; NEUROPROTECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84876280381     PISSN: 09534180     EISSN: 18758584     Source Type: Journal    
DOI: 10.1155/2013/705373     Document Type: Article

References (46)

1. O.R. Adam and J. Jankovic, Symptomatic treatment of Huntington disease, Neurotherapeutics 5 (2008), 181-197. (Pubitemid 351446213)
2. C.A. Ross and S.J. Tabrizi, Huntington's disease: from molecular pathogenesis to clinical treatment, Lancet Neurol 10 (2011), 83-98.
3. J.F. Gusella, N.S. Wexler, P.M. Conneally, S.L. Naylor, M.A. Anderson, R.E. Tanzi et al., A polymporphic DNA marker genetically linker to Huntington's disease, Nature 306 (1983), 234-238. (Pubitemid 14232350)
4. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes, Cell 72 (1993), 971-983.
5. W. Philips, K.M. Shannon and R.A. Barker, The current clinical management of Huntington's disease, Mov Disord 23 (2008), 1491-1504.
6. S.J. Tabrizi, D.R. Langbehn, B.R. Leavitt, R.A.C. Roos, A. Durr, D. Crauford et al., Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross sectional analysis of baseline data, Lancet Neurol 8 (2009), 791-801.
7. C. Wider and R. Luthi-Carter, Huntington's disease: clinical and aetiological aspects, Schweiz Arch Neurol Psychiatr 157 (2006), 378-383. (Pubitemid 46093200)
8. B.A. Haskins and M.B. Harrison, Huntington's disease, Curr Treat Option N 2 (2000), 243-262.
9. F.O. Walker, Huntington's disease, Lancet 369 (2007), 218-228. (Pubitemid 46107685)
10. D. Paleacu, Tetrabenazine in the treatment of Huntington's disease, Neuropsychiatr Dis Treat 3 (2007), 545-551. (Pubitemid 350090285)
11. S. Krobitsch and A.G. Kazantsev, Huntington's disease: from molecular basis to therapeutic advances, Int J Biochem Cell B 43 (2010), 20-24.
12. J.T. Greenamyre, Huntington's disease-making connections, N Engl J Med 365 (2007), 518-529.
13. E. Roze, F. Saudou and J. Caboche, Pathophysiology of Huntington's disease: from huntingtin functions to potential treatment, Curr Opin Neurol 21 (2008), 497-503.
14. S. Frank, Tetrabenazine: the first approved drug for the treatment if chorea in US patients with Huntington disease, Neuropsychiatr Dis Treat 6 (2010), 657-665.
15. H. Ryu, H.D. Rosas, S.M. Hersch and R.J. Ferrante, The therapeutic role of creatine in Huntington's disease, Pharmacol Therapeut 108 (2005), 193-207. (Pubitemid 41527084)
16. S. Tekin and J.L. Cummings, Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update, J Psychosom Res 53 (2002), 647-654. (Pubitemid 36292444)
17. J.P.P. van Vugt and R.A.C. Roos, Huntington's disease: options for controlling symptoms, CNS Drugs 11 (1999), 105-123. (Pubitemid 29113639)
18. V.M. Andre, C. Cepeda and M. Levine, Dopamine and glutamate in Huntington's disease: a balancing act, CNS Neurosci Ther 16 (2010), 163-178.
19. R.M. Bonelli and J.L.Cummings, Frontal-subcortical circuitry and behaviour, Dialogues Clin Neurosci 9 (2007), 141-151.
20. R. Bonelli and P. Hofmann, A systematic review of the treatment studies in Huntington's disease since 1990, Expert Opin Pharmacother 7 (2007), 1-13.
21. D. Moher, A. Liberati, J. Tetzlaff and D.G. Altman, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Ann Intern Med 151 (2009), 264-269.
22. S. Frank, W. Ondo, S. Fabn, C. Hunter, D. Oakes, S. Plumb et al., A study of chorea after tetrabenazine withdrawal in patients with Huntington's disease, Clin Neuropharmacol 31 (2008), 127-133. (Pubitemid 351787108)
23. Huntington Study Group, Tetrabenazine as antichorea therapy in Huntington disease: a randomised control trial, Neurology 66 (2006), 366-372.
24. J.P.P. van Vugt, S. Siesling, M.Vergeer, E.A. van derVelde and R.A.C. Roos, Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study, J Neurol Neurosurg Psychiatry 63 (1997), 35-39. (Pubitemid 27317358)
25. J. Deroover, F. Baro, R.P. Bourguignon and P. Smets, Tiapride versus placebo: a double-blind comparative study in the management ofHuntington's chorea, Curr Med Res Opin 9 (1984), 329-338. (Pubitemid 15180157)
26. R.A.C. Roos, O.J.S. Buruma, G.W. Bruyn, B. Kemp and E.A. van deVelde, Tiapride in the treatment of Huntington's chorea, Acta Neurol Scand 65 (1982), 45-50. (Pubitemid 12178846)
27. A. Lundin, E. Dietrichs, S. Haghighi,M.L.Goller, A. Heiberg, G. Loutfi et al., Efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease, Clin Neuropharm 33 (2010), 260-264.
28. L. Verhagen-Metman, M.J. Morris, C. Farmer, N.P. Gillespie, K. Mosby, J. Wuu et al., Huntington's disease: a randomised, controlled trial using the NMDA-antagonist amantadine, Neurology 59 (2002), 694-699.
29. P. O'Suilleabhain and R.B. Dewey, A randomised trial of amantadine in Huntington disease, Arch Neurol 60 (2003), 996-998. (Pubitemid 36858360)
30. K. Kieburtz, A. Feigin, M. McDermott, P. Como, D. Adwender, C. Zimmerman et al., A controlled trial of remacemide hydrochloride in Huntington's disease, Mov Disord 11 (1996), 273-277. (Pubitemid 26138825)
31. Huntington Study Group, A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease, Neurology 57 (2001), 397-404.
32. G.B. Landwehrmeyer, B. Dubois, J.G. de Yebenes, B. Kremer, W. Gaus, P.H. Kraus et al., Riluzole in Huntington's disease: a 3-year, randomised controlled study, Ann Neurol 62 (2007), 262-272. (Pubitemid 47525402)
33. Huntington Study Group, Dosage effects if riluzole in Huntington's disease: a multicentre placebo-controlled study, Neurology 61 (2003), 1551-1556.
34. B. Kremer, C.M. Clark, E.W. Almqvist, L.A. Raymond, P. Graf, C. Jacova et al., Influence of lamotrigine on progression of early Huntington's disease: a randomized clinical trial, Neurology 53 (1999), 1000-1011. (Pubitemid 29442116)
35. E. Cubo, K.M. Shannon, D. Tracy, J.A. Jaglin, B.A. Bernard, J. Wuu et al., Effect of donepezil onmotor and cognitive function in Huntington disease, Neurology 67 (2006), 1268-1271. (Pubitemid 44563842)
36. I. Shoulson, C. Odoroff, D. Oakes, J. Behr, D. Goldblatt, E. Caine et al., A controlled clinical trial of baclofen as protective therapy in early Huntington's disease, Ann Neurol 25 (1989), 252-259. (Pubitemid 19085516)
37. A. Curtis, I. Mitchell, S. Patel, N. Ives and H. Rickards, A pilot study using nabilone for symptomatic treatment in Huntington's disease, Mov Disord 24 (2009), 2254-2259.
38. P.G. Como, A.J. Rubin, C.F. O'Brien, K. Lawler, C. Hickey, A.E. Rubin et al., A controlled trial of fluoxetine in nondepressed patients with Huntington's disease, Mov Disord 12 (1997), 397-401. (Pubitemid 27216139)
39. B.K. Puri, B.R. Leavitt, M.R. Hayden, C.A. Ross, A. Rosenblatt, J.T. Greenamyre et al., Ethyl-EPA in Huntington's disease: a double-blind, randomized, placebo-controlled trial, Neurology 65 (2005), 286-292. (Pubitemid 41022376)
40. Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease, Arch Neurol 65 (2008), 1582-1589.
41. L.J. Beglinger, W.H. Adams, H. Paulson, J.G. Fiedorowicz, D.R. Langbehn, K. Duff et al., Randomised controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease, J Clin Psychopharmacol 29 (2009), 484-487.
42. P. Verbessem, J. Lemiere, B.O. Eijnde, S. Swinnen, L. Vanhees, M. van Leemputte et al., Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial, Neurology 61 (2003), 925-930. (Pubitemid 37248646)
43. A.D. Blackwell, N.S. Paterson, R.A. Barker, T.W. Robbins and B.J. Sahakian, The effects of modafinil on mood and cognition in Huntington's disease, Psychopharmacology 199 (2008), 29-36.
44. K. Kieburtz, M.P. McDermott, T.S. Voss, J. Corey-Bloom, L.M. Deuel, R. Dorsey et al., A randomized, placebocontrolled trial of latrepirdine in Huntington disease, Arch Neurol 67 (2010), 154-160.
45. E. van Duijn, Treatment of irritability in Huntington's disease, Curr Treat Option Neurol 12 (2010), 424-433.
46. R.M. Bonelli and G.K. Wenning, Pharmacological management of Huntington's disease: and evidence-based review, Curr Pharm Des 12 (2006), 2701-2720.